Nottingham life sciences firm snaps up counterpart
Register for free to receive latest news stories direct to your inboxRegister
Sygnature Discovery, the Nottingham drug discovery and pre-clinical services company, has swooped for Alderley Oncology, a Cheshire-based counterpart.
Until the acquisition, Alderley Oncology was run by Bruntwood SciTech, owners of Alderley Park. The value of the deal has not been disclosed.
Alderley Oncology was established by Jane Kendrew in 2017. She said: “We are delighted to be joining Sygnature Discovery.
“We look forward to working with them as part of the wider team serving the oncology drug discovery community, and patients living with cancer.”
Dr Stuart Onions, director of research management at Sygnature, said: “We are pleased to welcome Jane and her colleagues to Sygnature Discovery.
“The team’s expertise in oncology and immuno-oncology in vivo models will significantly enhance our integrated oncology provision, delivering further value to our integrated projects for clients and, importantly, allow us to more efficiently and effectively deliver potential new therapeutics into pre-clinic development.”
Sygnature CEO Dr Simon Hirst added: “The acquisition of Alderley Oncology expands and enhances our drug discovery services portfolio, and further boosts our on-going investments in oncology,” he said. “We have already delivered five oncology pre-clinical candidates for clients. Sygnature has an expanding portfolio of integrated programmes in oncology and immuno-oncology with clients in the USA and Europe. The added expertise gained from Alderley Oncology will greatly assist in advancing these projects into pre-clinical development.”
Dr Kath Mackay, managing director of Bruntwood SciTech – Alderley Park, said: “We’re really proud of the amazing work Jane and her team have delivered over the last three years to create Alderley Oncology and grow it into a successful business. Now is the time for it to scale with the support of Sygnature and accelerate its growth, so that it can play an ever more critical role in supporting UK and global oncology development.”